Annual report
2784.TEDINET S100OHEM
Period2021-04-01 → 2022-03-31
Filed2022-06-28
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.59T | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥2.61T | 2020-04-01 → 2021-03-31 | Cons. | Net sales |
| Revenue | ¥2.70T | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.64T | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.60T | 2017-04-01 → 2018-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥29.1bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Operating income | ¥27.9bn | 2020-04-01 → 2021-03-31 | Cons. | Operating income |
| Ordinary income | ¥32.6bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥31.9bn | 2020-04-01 → 2021-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥57.2bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥55.1bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥51.9bn | 2017-04-01 → 2018-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥48.2bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥36.5bn | 2020-04-01 → 2021-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥32.2bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥24.5bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥40.3bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥41.7bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥35.6bn | 2017-04-01 → 2018-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥32.2bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Net income | ¥24.5bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss |
| Total assets | ¥1.30T | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥1.32T | at 2021-03-31 | Cons. | Assets |
| Total assets | ¥1.35T | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.34T | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.34T | at 2018-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥832.2bn | at 2022-03-31 | Cons. | Liabilities |
| Total liabilities | ¥826.7bn | at 2021-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥471.8bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥490.0bn | at 2021-03-31 | Cons. | Net assets |
| Net assets / equity | ¥474.9bn | at 2020-03-31d | Cons. | Net assets |
| Net assets / equity | ¥442.1bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥435.9bn | at 2018-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥180.4bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥170.3bn | at 2021-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥179.1bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥169.1bn | at 2021-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥209.3bn | at 2020-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥205.1bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥195.6bn | at 2018-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥36.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥21.2bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥33.8bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥46.9bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥47.6bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | ¥2.3bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥4.7bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥17.0bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥12.9bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥10.2bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥29.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥14.5bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥12.6bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥24.9bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥9.9bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥153.57 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥115.75 | 2020-04-01 → 2021-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥190.26 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥195.91 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥164.25 | 2017-04-01 → 2018-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥2,330.36 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,313.66 | at 2021-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,237.89 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,083.03 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,006.53 | at 2018-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 36.2% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.2% | at 2021-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.0% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.9% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.5% | at 2018-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 6.7% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.1% | 2020-04-01 → 2021-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.8% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.5% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.6% | 2017-04-01 → 2018-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 11,925 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 12,045 | at 2021-03-31 | Cons. | Number of employees |
| Employees | 12,074 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 12,076 | at 2019-03-31d | Cons. | Number of employees |
| Employees | 11,901 | at 2018-03-31d | Cons. | Number of employees |
| Revenue | ¥17.2bn | 2021-04-01 → 2022-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥25.3bn | 2020-04-01 → 2021-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥26.1bn | 2019-04-01 → 2020-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥22.0bn | 2018-04-01 → 2019-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥19.6bn | 2017-04-01 → 2018-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥15.2bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Operating income | ¥23.4bn | 2020-04-01 → 2021-03-31 | Standalone | Operating income |
| Ordinary income | ¥15.4bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥23.7bn | 2020-04-01 → 2021-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥24.5bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥20.2bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥18.0bn | 2017-04-01 → 2018-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥13.7bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥24.1bn | 2020-04-01 → 2021-03-31 | Standalone | Income before income taxes |
| Net income | ¥13.6bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥23.9bn | 2020-04-01 → 2021-03-31 | Standalone | Profit loss |
| Net income | ¥22.3bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥20.2bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥17.9bn | 2017-04-01 → 2018-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥265.3bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥277.5bn | at 2021-03-31 | Standalone | Assets |
| Total assets | ¥260.4bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥248.3bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥252.8bn | at 2018-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥17.7bn | at 2022-03-31 | Standalone | Liabilities |
| Total liabilities | ¥16.2bn | at 2021-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥247.6bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥261.3bn | at 2021-03-31 | Standalone | Net assets |
| Net assets / equity | ¥248.3bn | at 2020-03-31d | Standalone | Net assets |
| Net assets / equity | ¥236.1bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥239.5bn | at 2018-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥21.0bn | at 2022-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥33.0bn | at 2021-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥64.88 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥112.78 | 2020-04-01 → 2021-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥105.2 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥94.74 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥82.64 | 2017-04-01 → 2018-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥54 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥53 | 2020-04-01 → 2021-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥48 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥39 | 2017-04-01 → 2018-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,223.58 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,234.61 | at 2021-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,173.2 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,115.63 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,105.38 | at 2018-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 93.3% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 94.2% | at 2021-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 95.4% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 95.1% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 94.7% | at 2018-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 5.3% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.4% | 2020-04-01 → 2021-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.2% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.5% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.6% | 2017-04-01 → 2018-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 235,017,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 235,017,000 | at 2021-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 235,017,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 235,017,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 235,017,000 | at 2018-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 44 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 38 | at 2021-03-31 | Standalone | Number of employees |
| Employees | 38 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 38 | at 2019-03-31d | Standalone | Number of employees |
| Employees | 42 | at 2018-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 84
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2021-04-01 → 2022-03-31 | ¥2.1bn |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥2.1bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥29.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥29.1bn |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | ¥15.5bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | ¥332m |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥9.6bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥6.0bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | employees | at 2022-03-31 | 8931 pure |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥2.29T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥2.27T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥15.7bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment assets | at 2022-03-31 | ¥1.12T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥24.8bn |
| Manufacturing Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥3.9bn |
| Manufacturing Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥3.3bn |
| Manufacturing Businessreportable segment | employees | at 2022-03-31 | 1370 pure |
| Manufacturing Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥47.4bn |
| Manufacturing Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥34.6bn |
| Manufacturing Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥12.8bn |
| Manufacturing Businessreportable segment | segment assets | at 2022-03-31 | ¥70.5bn |
| Manufacturing Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥1.9bn |
| Medical Related Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥426m |
| Medical Related Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥387m |
| Medical Related Businessreportable segment | employees | at 2022-03-31 | 1108 pure |
| Medical Related Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥34.5bn |
| Medical Related Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥34.5bn |
| Medical Related Businessreportable segment | segment assets | at 2022-03-31 | ¥16.7bn |
| Medical Related Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥183m |
| Self Medication Products Wholesaling Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥306m |
| Self Medication Products Wholesaling Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥357m |
| Self Medication Products Wholesaling Businessreportable segment | employees | at 2022-03-31 | 400 pure |
| Self Medication Products Wholesaling Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥244.8bn |
| Self Medication Products Wholesaling Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥244.2bn |
| Self Medication Products Wholesaling Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥610m |
| Self Medication Products Wholesaling Businessreportable segment | segment assets | at 2022-03-31 | ¥83.0bn |
| Self Medication Products Wholesaling Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥1.9bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2021-04-01 → 2022-03-31 | ¥14.2bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-04-01 → 2022-03-31 | ¥10.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2022-03-31 | ¥2.61T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2022-03-31 | ¥2.59T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥29.1bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-03-31 | ¥1.29T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2022-03-31 | ¥28.8bn |
| Reconciling Itemsreconciling | capex | 2020-04-01 → 2021-03-31 | ¥2.1bn |
| Reconciling Itemsreconciling | depreciation | 2020-04-01 → 2021-03-31 | ¥2.3bn |
| Reconciling Itemsreconciling | revenue | 2020-04-01 → 2021-03-31 | −¥25.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2020-04-01 → 2021-03-31 | −¥25.1bn |
| Reconciling Itemsreconciling | segment assets | at 2021-03-31 | ¥34.4bn |
| Reconciling Itemsreconciling | segment profit | 2020-04-01 → 2021-03-31 | ¥332m |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥22.9bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥5.1bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥2.30T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥2.28T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥15.2bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment assets | at 2021-03-31 | ¥1.11T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥25.6bn |
| Manufacturing Businessreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥3.6bn |
| Manufacturing Businessreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥3.1bn |
| Manufacturing Businessreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥42.6bn |
| Manufacturing Businessreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥33.2bn |
| Manufacturing Businessreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥9.4bn |
| Manufacturing Businessreportable segment | segment assets | at 2021-03-31 | ¥65.6bn |
| Manufacturing Businessreportable segment | segment profit | 2020-04-01 → 2021-03-31 | −¥144m |
| Medical Related Businessreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥673m |
| Medical Related Businessreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥355m |
| Medical Related Businessreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥33.3bn |
| Medical Related Businessreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥33.3bn |
| Medical Related Businessreportable segment | segment assets | at 2021-03-31 | ¥17.5bn |
| Medical Related Businessreportable segment | segment profit | 2020-04-01 → 2021-03-31 | −¥360m |
| Self Medication Products Wholesaling Businessreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥280m |
| Self Medication Products Wholesaling Businessreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥410m |
| Self Medication Products Wholesaling Businessreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥261.7bn |
| Self Medication Products Wholesaling Businessreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥261.2bn |
| Self Medication Products Wholesaling Businessreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥527m |
| Self Medication Products Wholesaling Businessreportable segment | segment assets | at 2021-03-31 | ¥88.0bn |
| Self Medication Products Wholesaling Businessreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥2.5bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2020-04-01 → 2021-03-31 | ¥27.4bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2020-04-01 → 2021-03-31 | ¥8.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2020-04-01 → 2021-03-31 | ¥2.64T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2020-04-01 → 2021-03-31 | ¥2.61T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥25.1bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2021-03-31 | ¥1.28T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2020-04-01 → 2021-03-31 | ¥27.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,156
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)有限責任 あずさ監査法人 | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)細 矢 聡 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)渡 邊 崇 | |
| Cpa3 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)斉 藤 直 樹 | |
| Key audit matters consolidated (text) | FilingDateInstant | Text · Plus | |
| Overview kam consolidated (text) | FilingDateInstant | Text · Plus | |
| Short description kam consolidated | FilingDateInstant_Row1Member | Original text (Japanese)独占禁止法関連損失引当金の見積りの妥当性 | |
| Description including reason kam consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Reference kam consolidated | FilingDateInstant_Row1Member | Original text (Japanese)注記事項「（重要な会計上の見積り）1.独占禁止法に関連して将来に発生しうる損失の見積り」 | |
| Reference2 kam consolidated | FilingDateInstant_Row1Member | Original text (Japanese)注記事項「（連結貸借対照表関係）6.偶発債務」 | |
| Auditors response kam consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Short description kam consolidated | FilingDateInstant_Row2Member | Original text (Japanese)非上場のヘルスケア関連企業等に対する投資の評価の合理性 | |
| Description including reason kam consolidated (text) | FilingDateInstant_Row2Member | Text · Plus | |
| Auditors response kam consolidated (text) | FilingDateInstant_Row2Member | Text · Plus | |
| Other information consolidated (text) | FilingDateInstant | Text · Plus | |
| Independent auditors report non consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)有限責任 あずさ監査法人 | |
| Cpa1 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)細 矢 聡 | |
| Cpa2 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)渡 邊 崇 | |
| Cpa3 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)斉 藤 直 樹 | |
| Key audit matters non consolidated (text) | FilingDateInstant | Text · Plus | |
| Overview kam non consolidated (text) | FilingDateInstant | Text · Plus | |
| Short description kam non consolidated | FilingDateInstant_Row1Member | Original text (Japanese)非上場のヘルスケア関連企業等に対する投資の評価の合理性 | |
| Description including reason kam non consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Auditors response kam non consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Other information non consolidated (text) | FilingDateInstant | Text · Plus | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior4YearDuration | 2602917000000 | JPY |
| Net sales (5-year summary) | Prior3YearDuration | 2640511000000 | JPY |
| Net sales (5-year summary) | Prior2YearDuration | 2698511000000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 2610427000000 | JPY |
| Net sales (5-year summary) | CurrentYearDuration | 2585643000000 | JPY |
| Ordinary income loss (5-year summary) | Prior4YearDuration | 51861000000 | JPY |
| Ordinary income loss (5-year summary) | Prior3YearDuration | 55138000000 | JPY |
| Ordinary income loss (5-year summary) | Prior2YearDuration | 57170000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 31918000000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYearDuration | 32576000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior4YearDuration | 35589000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior3YearDuration | 41724000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior2YearDuration | 40273000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 24501000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYearDuration | 32182000000 | JPY |
| Comprehensive income (5-year summary) | Prior4YearDuration | 50236000000 | JPY |
| Comprehensive income (5-year summary) | Prior3YearDuration | 29837000000 | JPY |
| Comprehensive income (5-year summary) | Prior2YearDuration | 43482000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | 27119000000 | JPY |
| Comprehensive income (5-year summary) | CurrentYearDuration | 8461000000 | JPY |
| Net assets (5-year summary) | Prior4YearInstant | 435934000000 | JPY |
| Net assets (5-year summary) | Prior3YearInstant | 442081000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |